For nearly 30 years, Perceptive has been at the forefront of neuroscience imaging solutions, developing and delivering cutting-edge services for over 650 preclinical, early-phase, and late-phase clinical studies across neuro-degenerative, neuro-oncology, neuro-psychiatric, and rare disease indications.
Perceptive’s image analysis team leverages industry-leading validated and exploratory tools for neuro PET, SPECT, CT, and MRI analysis pipelines supporting study endpoints. Perceptive has analyzed thousands of clinical scans across Neuroscience indications including Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Multiple Sclerosis, Neuro-oncology, and more.
Comprehensive analysis pipelines utilize SUVR, Centiloids, state-of-the-art AmyloidIQ and TauIQ as well as volumetrics, advanced Diffusion Tensor Imaging (DTI), functional Magnetic Resonance Imaging (fMRI), and neuromelanin algorithms. In addition, Perceptive supports semi-qualitative visual neuro-radiology reads.
Perceptive supports your Neuroscience studies with rigorous scientific expertise and operational excellence within the clinical trial framework.
You can rely on Perceptive to help you minimize risks and optimize Neuroscience development outcomes by:
Stay on top of industry trends and learn how Perceptive is helping sponsors and CROs design and implement clinical trials effectively – and efficiently.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
